NovaBay Pharmaceuticals, Inc. (NBY) announced Monday an agreement to commercialize BioStem Technologies, Inc.'s (BSEM) Amniotic Tissue Allograft as Avenova Allograft. The company plans to launch Avenova Allograft in the coming weeks.
In pre-market activity on the NYSE, NovaBay shares were surging around 92 percent to trade at $1.19.
Amniotic Tissue Allograft is intended for use as a protective covering during the repair of ocular surfaces. It provides a protective environment or covering for repair of the cornea and conjunctiva, helping ocular surface to return to a healthier state.
Avenova Allograft is the only optic allograft manufactured using BioStem's patented six-step BioREtain process that preserves the natural integrity of the placental tissue.
NovaBay said it intends to commercialize the prescription-only product as Avenova Allograft to leverage its Avenova eyecare brand and encourage use with other Avenova products.
The new NovaBay-branded product will compete in the global ophthalmology amniotic membrane market estimated at $403.6 million in 2022, and is expected to grow at 9.8% per year between 2023-2030.
Medically necessary procedures with the Avenova Allograft will be reimbursed through Medicare.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.